MedPath

FUDANZHANGJIANG

Ownership
-
Established
1996-11-11
Employees
948
Market Cap
-
Website
http://www.fd-zj.com
Introduction

The company was founded in November 1996 in the Zhangjiang Hi-Tech Park in Pudong, Shanghai, with well-known enterprises such as Shanghai Pharmaceutical Group Co., Ltd. as shareholders of the company. It is mainly engaged in innovative research and development, manufacturing and marketing of biomedicine. Main products: Dermatological products, anti-tumor products, etc. Corporate honors: Jiangsu High-tech Enterprise, 2017 Economic Outstanding Contribution Award, Shanghai Enterprise Technology Center, etc.

Aminolaevulinic Acid Photodynamic Therapy of Cervical Persistent HPV Infection and Cervical Neoplasia

Phase 2
Completed
Conditions
Cervical Persistent High Risk HPV Infection
Cervical Intraepithelial Neoplasia
Interventions
Drug: Aminolaevulinic acid photodynamic therapy
First Posted Date
2014-12-02
Last Posted Date
2019-06-12
Lead Sponsor
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Target Recruit Count
73
Registration Number
NCT02304770
Locations
🇨🇳

Qilu Hospital of Shandong University, Jinan, Shandong, China

🇨🇳

The First Affliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China

🇨🇳

The Obstetrics & Gynecology Hospital of Fudan University, Shanghai, Shanghai, China

and more 1 locations

Tolerance and Pharmacokinetics of T0001 in Healthy Adult Chinese Volunteers

Phase 1
Completed
Conditions
Rheumatic Diseases
Interventions
Drug: T0001,10mg
Drug: T0001,20mg
Drug: T0001,35mg
Drug: T0001,50mg
Drug: T0001,65mg
Drug: T0001,75mg
First Posted Date
2014-11-14
Last Posted Date
2019-07-09
Lead Sponsor
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Target Recruit Count
56
Registration Number
NCT02291471
Locations
🇨🇳

Phase I laboratory of Peking University People's Hospital, Beijing, Beijing, China

Assess Bioequivalence of Two Formulations of Doxorubicin Hydrochloride Liposome in Female Patients With Ovarian Cancer

Phase 1
Completed
Conditions
Ovarian Cancer
Interventions
First Posted Date
2014-09-11
Last Posted Date
2017-06-05
Lead Sponsor
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Target Recruit Count
30
Registration Number
NCT02237690
Locations
🇨🇳

Cancer Institute& Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China

🇨🇳

QiLu Hospital of Shandong University, Jinan, Shandong, China

🇨🇳

Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

Deuteporfin Tolerance and Pharmacokinetics in Healthy Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: placebo
First Posted Date
2011-11-29
Last Posted Date
2012-05-16
Lead Sponsor
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Target Recruit Count
32
Registration Number
NCT01481597
Locations
🇨🇳

Xiangya Hospital of Central-South University, Changsha, Hunan, China

© Copyright 2025. All Rights Reserved by MedPath